Key Highlights
- KORU reported second-quarter net Revenue of $12.0 million, up 18.2% year over year, with gross Margin of about 65% and a return to positive net income.
- The company updated its 2026 guidance to revenue of $47.5 million to $48.5 million, representing 15% to 18% growth.
- KORU completed a CEO transition in mid-2026, with Adam Kalbermatten assuming the role.
KORU Medical Systems has spent 2026 converting a niche in subcutaneous drug delivery into steadier financial results, returning to profitability even as its shares eased to around $3.15 in early September. The maker of the FREEDOM infusion platform sits at the intersection of medical devices and specialty drug administration, a corner of healthcare with durable, recurring demand. For KORU Medical Systems (NASDAQ: KRMD), the recent softness in the stock contrasts with a Business that has been trending in the right direction.
Company and Latest Development
KORU Medical Systems, headquartered in Mahwah, New Jersey, develops and manufactures subcutaneous infusion systems used to deliver medications such as immunoglobulin therapies outside the hospital, led by its FREEDOM syringe infusion platform and the FreedomEDGE device. On August 5, 2026, the company reported second-quarter results and updated its full-year guidance, posting net revenue of $12.0 million, up 18.2% year over year, with gross margin of about 65% and a return to positive Net Income of roughly $0.25 million.
What Is Driving Attention Around KRMD?
The supplied headline says KRMD is "turning lower" and that investors are reassessing the company. The modest daily decline does not map to a single confirmed catalyst; the more concrete developments are mixed. On the positive side, KORU returned to profitability and firmed up its full-year outlook. On the other, analysts at Craig-Hallum trimmed their price target to $6 from $7 following the quarter, and earlier in the summer a law firm publicized a Shareholder "investigation," a type of solicitation common around public companies that does not by itself establish any wrongdoing.
Key Numbers and Company Position
Second-quarter net revenue reached $12.0 million, an 18.2% increase, with Gross Profit of $7.8 million at a 65.1% margin and net income of about $0.25 million. KORU updated its 2026 guidance to revenue of $47.5 million to $48.5 million, representing 15% to 18% growth, with positive adjusted EBITDA. For context, the company reported full-year 2025 revenue of about $41.1 million. KRMD trades on the Nasdaq with a market Capitalization near $145 million, and shares stood at roughly $3.15 on September 9, 2026. KORU completed a CEO transition in mid-2026, with Adam Kalbermatten assuming the role.
What Could Come Next?
The next Quarterly Report will test whether KORU can deliver against its full-year revenue range and sustain positive adjusted EBITDA. Investors may watch adoption of the FreedomEDGE system, progress in its drug-delivery partnerships with pharmaceutical companies, and any new real-world data supporting its platform. Regulatory milestones, such as its earlier EU MDR certification for the Freedom60 pump, and expansion into additional therapy areas could also influence the story, along with participation in investor conferences.
Risks to Watch
KORU operates in a competitive medical-device niche and depends significantly on immunoglobulin-therapy Demand and on partnerships with drug developers, creating concentration risk. Reimbursement dynamics, Manufacturing and Supply considerations, and the execution demands of a recent Leadership transition all bear watching. Although the company returned to profitability, margins and net income remain modest and could fluctuate quarter to quarter. Publicized shareholder investigations, while common, can weigh on sentiment even without a substantive finding.
Conclusion
KORU Medical Systems heads into late 2026 with double-digit revenue growth, a return to profitability and updated full-year guidance, even as its shares have drifted lower. The recent price softness lacks a single clearly identifiable catalyst and coincides with an analyst target trim and routine legal solicitations rather than a confirmed operational setback. Investors following KRMD may be watching execution against full-year guidance, adoption of its infusion platform, pharmaceutical Partnership progress and the company's ability to sustain positive adjusted EBITDA.






Please wait processing your request...